Given the immune dysregulation underlying the disease, the available therapies are based on immunomodulatory drugs such as conventional synthetic disease-modifying antirheumatic drugs (DMARDs) (e.g., methotrexate) or biologic DMARDs targeting key cytokines (e.g., TNF inhibitors, IL-6 inhibitors) or cells (e.g., the selective T-cell costimulation modulator abatacept of the B-cell-depleting agent rituximab) involved in RA immunopathogenesis [2]. The gene discussed is IL6; the disease is rheumatoid arthritis.